Concert Pharmaceuticals Inc (NASDAQ:CNCE) Director Richard Aldrich sold 31,236 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $19.14, for a total transaction of $597,857.04. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Concert Pharmaceuticals Inc (CNCE) traded down $0.23 during trading on Thursday, hitting $19.71. 515,133 shares of the stock traded hands, compared to its average volume of 743,733. Concert Pharmaceuticals Inc has a fifty-two week low of $8.61 and a fifty-two week high of $30.71. The firm has a market cap of $449.30, a PE ratio of 5.26 and a beta of 1.67.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. sell-side analysts expect that Concert Pharmaceuticals Inc will post 4.1 earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Concert Pharmaceuticals by 11.0% in the 2nd quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock valued at $10,553,000 after buying an additional 74,801 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Concert Pharmaceuticals by 11.2% in the 2nd quarter. Northern Trust Corp now owns 243,989 shares of the biotechnology company’s stock valued at $3,403,000 after buying an additional 24,622 shares in the last quarter. State Street Corp boosted its holdings in shares of Concert Pharmaceuticals by 9.5% in the 2nd quarter. State Street Corp now owns 300,093 shares of the biotechnology company’s stock valued at $4,186,000 after buying an additional 26,024 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Concert Pharmaceuticals in the 3rd quarter valued at $843,000. Finally, Schwab Charles Investment Management Inc. boosted its holdings in shares of Concert Pharmaceuticals by 47.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 32,122 shares of the biotechnology company’s stock valued at $449,000 after buying an additional 10,400 shares in the last quarter. Institutional investors and hedge funds own 65.29% of the company’s stock.

CNCE has been the subject of several analyst reports. Zacks Investment Research cut shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, September 22nd. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Concert Pharmaceuticals in a report on Friday, October 20th. Stifel Nicolaus reiterated a “buy” rating and set a $30.00 price target on shares of Concert Pharmaceuticals in a report on Sunday, October 22nd. Mizuho initiated coverage on shares of Concert Pharmaceuticals in a report on Thursday, October 26th. They set a “buy” rating and a $23.00 price target for the company. Finally, TheStreet upgraded shares of Concert Pharmaceuticals from a “d” rating to a “c+” rating in a report on Wednesday, November 29th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $24.33.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Concert Pharmaceuticals Inc (CNCE) Director Sells 31,236 Shares of Stock” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://theolympiareport.com/2018/01/18/insider-selling-concert-pharmaceuticals-inc-cnce-director-sells-31236-shares-of-stock.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.